Clinical-Radiological Characteristic for Predicting Ultra-Early Recurrence After Liver Resection in Solitary Hepatocellular Carcinoma Patients

References

• Villanueva A, Longo DL. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra1713263
   PubMed Web of Science ®Google Scholar
• Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late Phase Intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200–207. doi:10.1016/s0168-8278(02)00360-4
   PubMed Web of Science ®Google Scholar
• Du ZG, Wei YG, Chen KF, Li B. Risk factors associated with early and late recurrence after curative resection of hepatocellular carcinoma: a single institution’s experience with 398 consecutive patients. Hepatobiliary Pancreat Dis Int. 2014;13(2):153–161. doi:10.1016/s1499-3872(14)60025-4
   PubMed Web of Science ®Google Scholar
• Zhang Z, Jiang H, Chen J, et al. Hepatocellular carcinoma: radiomics nomogram on gadoxetic acid-enhanced MR imaging for early postoperative recurrence prediction. Cancer Imaging. 2019;19(1):22. doi:10.1186/s40644-019-0209-5
   PubMed Web of Science ®Google Scholar
• Xing H, Zhang WG, Cescon M, et al. Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study. HPB. 2020;22(5):677–689. doi:10.1016/j.hpb.2019.09.006
   PubMed Web of Science ®Google Scholar
• Xu W, Liu F, Shen X, Li R. Prognostic nomograms for patients with Hepatocellular carcinoma after curative hepatectomy, with a focus on recurrence timing and post-recurrence management. J Hepatocell Carcinoma. 2020;7:233–256. doi:10.2147/JHC.S271498
   PubMed Web of Science ®Google Scholar
• Ma L, Deng K, Zhang C, et al. Nomograms for predicting Hepatocellular carcinoma recurrence and overall postoperative patient survival. Front Oncol. 2022;12:843589. doi:10.3389/fonc.2022.843589
   PubMed Web of Science ®Google Scholar
• Li Q, Wei Y, Zhang T, et al. Predictive models and early postoperative recurrence evaluation for hepatocellular carcinoma based on gadoxetic acid-enhanced MR imaging. Insights Imaging. 2023;14(1):4. doi:10.1186/s13244-022-01359-5
   PubMed Web of Science ®Google Scholar
• Nevola R, Ruocco R, Criscuolo L, et al. Predictors of early and late hepatocellular carcinoma recurrence. World J Gastroenterol. 2023;29(8):1243–1260. doi:10.3748/wjg.v29.i8.1243
   PubMed Web of Science ®Google Scholar
• Inoue Y, Suzuki Y, Ota M, et al. The management of recurrence of Hepatocellular carcinoma occurring within 6 months after hepatic resection: a Comparative Study using a propensity score matching analysis. J Gastrointest Cancer. 2022;53(2):272–281. doi:10.1007/s12029-021-00585-2
   PubMed Web of Science ®Google Scholar
• Zheng J, Cai J, Tao L, et al. Comparison on the efficacy and prognosis of different strategies for intrahepatic recurrent hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis. Int J Surg. 2020;83:196–204. doi:10.1016/j.ijsu.2020.09.031
   PubMed Web of Science ®Google Scholar
• Serenari M, Han KH, Ravaioli F, et al. A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma. J Hepatol. 2020;73(4):855–862. doi:10.1016/j.jhep.2020.04.032
   PubMed Web of Science ®Google Scholar
• Liu D, Song T. Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China. Biosci Trends. 2021;15(3):142–147. doi:10.5582/bst.2021.01083
   PubMed Web of Science ®Google Scholar
• Yin Z, Chen D, Liang S, Li X. Neoadjuvant therapy for Hepatocellular carcinoma. J Hepatocell Carcinoma. 2022;9:929–946. doi:10.2147/JHC.S357313
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang B, Chen XP. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front Med. 2021;15(2):155–169. doi:10.1007/s11684-021-0848-3
   PubMed Web of Science ®Google Scholar
• Feng LH, Sun HC, Zhu XD, et al. Prognostic nomograms and risk classifications of outcomes in very early-stage hepatocellular carcinoma patients after hepatectomy. Eur J Surg Oncol. 2021;47(3 Pt B):681–689. doi:10.1016/j.ejso.2020.10.039
   PubMed Web of Science ®Google Scholar
• Chan AWH, Zhong J, Berhane S, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol. 2018;69(6):1284–1293. doi:10.1016/j.jhep.2018.08.027
   PubMed Web of Science ®Google Scholar
• Zhang C, Yang R, Wang X, et al. LI-RADS morphological type predicts prognosis of patients with Hepatocellular carcinoma after radical resection. Ann Surg Oncol. 2023. doi:10.1245/s10434-023-13494-4
   Web of Science ®Google Scholar
• Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with Hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–853. doi:10.1053/j.gastro.2015.12.041
   PubMed Web of Science ®Google Scholar
• Chernyak V, Fowler KJ, Kamaya A, et al. Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of Hepatocellular carcinoma in at-risk patients. Radiology. 2018;289(3):816–830. doi:10.1148/radiol.2018181494
   PubMed Web of Science ®Google Scholar
• Chernyak V, Santillan CS, Papadatos D, Sirlin CB. LI-RADS® algorithm: CT and MRI. Abdom Radiol. 2018;43(1):111–126. doi:10.1007/s00261-017-1228-y
   PubMed Web of Science ®Google Scholar
• Mulé S, Galletto Pregliasco A, Tenenhaus A, et al. Multiphase liver MRI for identifying the macrotrabecular-massive subtype of Hepatocellular carcinoma. Radiology. 2020;295(3):562–571. doi:10.1148/radiol.2020192230
   PubMed Web of Science ®Google Scholar
• Chen J, Xia C, Duan T, et al. Macrotrabecular-massive hepatocellular carcinoma: imaging identification and prediction based on gadoxetic acid-enhanced magnetic resonance imaging. Eur Radiol. 2021;31(10):7696–7704. doi:10.1007/s00330-021-07898-7
   PubMed Web of Science ®Google Scholar
• Kang HJ, Kim H, Lee DH, et al. Gadoxetate-enhanced MRI features of proliferative Hepatocellular carcinoma are prognostic after surgery. Radiology. 2021;300(3):572–582. doi:10.1148/radiol.2021204352
   PubMed Web of Science ®Google Scholar
• Xu XF, Wu H, Li JD, et al. Association of tumor morphology with long-term prognosis after liver resection for patients with a solitary huge hepatocellular carcinoma-a multicenter propensity score matching analysis. Hepatobiliary Surg Nutr. 2023;12(3):314–327. doi:10.21037/hbsn-21-423
   PubMed Web of Science ®Google Scholar
• Hui AM, Takayama T, Sano K, et al. Predictive value of gross classification of hepatocellular carcinoma on recurrence and survival after hepatectomy. J Hepatol. 2000;33(6):975–979. doi:10.1016/s0168-8278(00)80131-2
   PubMed Web of Science ®Google Scholar
• Murakata A, Tanaka S, Mogushi K, et al. Gene expression signature of the gross morphology in Hepatocellular carcinoma. Ann Surg. 2011;253(1):94–100. doi:10.1097/SLA.0b013e3181f9bc00
   PubMed Web of Science ®Google Scholar
• Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–1370. doi:10.1200/JCO.2007.12.9791
   PubMed Web of Science ®Google Scholar
• Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in Hepatocellular carcinoma. Liver Int. 2019;39(12):2214–2229. doi:10.1111/liv.14223
   PubMed Web of Science ®Google Scholar
• Lu Z, Zuo B, Jing R, et al. Dendritic cell-derived exosomes elicit tumor regression in autochthonous Hepatocellular carcinoma mouse models. J Hepatol. 2017;67(4):739–748. doi:10.1016/j.jhep.2017.05.019
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee Y, Lee M, et al. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with Hepatocellular carcinoma. Br J Cancer. 2015;113(12):1666–1676. doi:10.1038/bjc.2015.430
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Mizukoshi E, Kobayashi E, et al. Association between high-avidity T-cell receptors, induced by α-fetoprotein-derived peptides, and anti-tumor effects in patients with Hepatocellular carcinoma. Gastroenterology. 2017;152(6):1395–1406.e10. doi:10.1053/j.gastro.2017.02.001
   PubMed Web of Science ®Google Scholar
• Xu XS, Wan Y, Song SD, et al. Model based on γ-glutamyl transferase and alkaline phosphatase for Hepatocellular carcinoma prognosis. World J Gastroenterol. 2014;20(31):10944–10952. doi:10.3748/wjg.v20.i31.10944
   PubMed Web of Science ®Google Scholar
• Agrawal S, Dhiman RK, Limdi JK. Evaluation of abnormal liver function tests. Postgrad Med J. 2016;92(1086):223–234. doi:10.1136/postgradmedj-2015-133715
   PubMed Web of Science ®Google Scholar
• Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable Hepatocellular carcinoma with portal vein tumor thrombus: a Randomized, Open-Label, Multicenter Controlled Study. J Clin Oncol. 2019;37(24):2141–2151. doi:10.1200/JCO.18.02184
   PubMed Web of Science ®Google Scholar